FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 358:2398-2400 May 29, 2008 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Fergusson, D. A. PubMed Citation

The aprotinin story began in 1987, when investigators reported that the use of the drug in patients undergoing repeat open-heart surgery decreased the need for blood transfusion by a factor of 8.¹ In 1993, the Food and Drug Administration (FDA) approved the use of aprotinin to reduce blood loss during coronary-artery bypass grafting, and the drug became widely used in cardiac surgery. In 2006, the use of aprotinin became controversial when the drug was associated with an increased risk of renal failure, myocardial infarction, stroke, and death in a large observational study.^2,3 Two subsequent cohort studies also linked aprotinin to . . . [Full Text of this Article]

Source Information

From the Vanderbilt University Center for Education and Research on Therapeutics (W.A.R., C.M.S.); the Departments of Preventive Medicine (W.A.R.) and Medicine (C.M.S.), Vanderbilt University School of Medicine; and the Geriatric Research, Education and Clinical Center, Nashville Veterans Affairs Medical Center (W.A.R.) — all in Nashville.

This article (10.1056/NEJMe0803514) was published at www.nejm.org on May 14, 2008.

Related Letters:

Aprotinin and Lysine Analogues in High-Risk Cardiac Surgery
Porte R. J., Mallette S. V., Burroughs A. K., Myles P. S., Ray W. A., Stein C. M.
Extract | Full Text | PDF  
N Engl J Med 2008; 359:1181-1182, Sep 11, 2008. Correspondence

This article has been cited by other articles:

• Jakobsen, C.-J., Sondergaard, F., Hjortdal, V. E., Johnsen, S. P. (2009). Use of aprotinin in cardiac surgery: effectiveness and safety in a population-based study. Eur. J. Cardiothorac. Surg. 36: 863-868 [Abstract] [Full Text]  
• Stamou, S. C., Reames, M. K., Skipper, E., Stiegel, R. M., Nussbaum, M., Geller, R., Robicsek, F., Lobdell, K. W. (2009). Aprotinin in cardiac surgery patients: is the risk worth the benefit?. Eur. J. Cardiothorac. Surg. 36: 869-875 [Abstract] [Full Text]  
• Carrel, T., Englberger, L. (2009). Editorial comment. Eur. J. Cardiothorac. Surg. 36: 875-876 [Full Text]  
• Henry, D. MBChB, Carless, P. BHSc MMedS, Fergusson, D. PhD MHA, Laupacis, A. MD MSc (2009). The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis. CMAJ 180: 183-193 [Abstract] [Full Text]  
• Brown, J. R. (2008). Invited Commentary. Ann. Thorac. Surg. 86: 1202-1203 [Full Text]  
• Porte, R. J., Mallette, S. V., Burroughs, A. K., Myles, P. S., Ray, W. A., Stein, C. M. (2008). Aprotinin and Lysine Analogues in High-Risk Cardiac Surgery. NEJM 359: 1181-1182 [Full Text]  
• (2008). Antifibrinolytics for Cardiac Surgery: Which Agent Is Best?. Journal Watch Cardiology 2008: 1-1 [Full Text]